Teachers Retirement System of The State of Kentucky Purchases 4,645 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)

Teachers Retirement System of The State of Kentucky raised its position in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) by 22.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 25,799 shares of the company’s stock after acquiring an additional 4,645 shares during the period. Teachers Retirement System of The State of Kentucky owned approximately 0.05% of Spyre Therapeutics worth $601,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in the company. MetLife Investment Management LLC boosted its holdings in shares of Spyre Therapeutics by 6.2% during the fourth quarter. MetLife Investment Management LLC now owns 21,382 shares of the company’s stock worth $498,000 after acquiring an additional 1,250 shares during the period. Huntington National Bank acquired a new stake in shares of Spyre Therapeutics in the fourth quarter valued at approximately $34,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Spyre Therapeutics in the fourth quarter valued at approximately $46,000. Arizona State Retirement System raised its position in shares of Spyre Therapeutics by 38.4% in the fourth quarter. Arizona State Retirement System now owns 10,115 shares of the company’s stock valued at $235,000 after buying an additional 2,805 shares in the last quarter. Finally, Rhumbline Advisers raised its position in shares of Spyre Therapeutics by 6.9% in the fourth quarter. Rhumbline Advisers now owns 57,657 shares of the company’s stock valued at $1,342,000 after buying an additional 3,722 shares in the last quarter. Institutional investors own 80.39% of the company’s stock.

Spyre Therapeutics Stock Performance

Shares of NASDAQ:SYRE opened at $14.67 on Tuesday. The company has a fifty day moving average of $16.42 and a 200-day moving average of $23.14. The company has a market capitalization of $884.25 million, a PE ratio of -1.96 and a beta of 3.05. Spyre Therapeutics, Inc. has a 52-week low of $10.91 and a 52-week high of $40.49.

Spyre Therapeutics (NASDAQ:SYRE) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.89) by $0.08. On average, equities analysts forecast that Spyre Therapeutics, Inc. will post -4.46 EPS for the current fiscal year.

Analysts Set New Price Targets

SYRE has been the subject of a number of analyst reports. Leerink Partners began coverage on shares of Spyre Therapeutics in a research report on Tuesday, April 8th. They issued an “outperform” rating and a $45.00 price target for the company. The Goldman Sachs Group upgraded shares of Spyre Therapeutics to a “strong-buy” rating in a research report on Tuesday, February 18th. Wedbush restated an “outperform” rating and set a $65.00 price objective on shares of Spyre Therapeutics in a research report on Monday, January 13th. Leerink Partnrs upgraded shares of Spyre Therapeutics to a “strong-buy” rating in a research report on Tuesday, April 8th. Finally, Wolfe Research began coverage on shares of Spyre Therapeutics in a research report on Tuesday, March 18th. They set an “outperform” rating and a $27.00 price objective for the company. Eight research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $49.57.

About Spyre Therapeutics

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).